Market Overview

Ligand Pharma, Glaxo Confirm PROMACTA Receives FDA Ok for New Indication

Share:
Related LGND
Revolade Recommended by CHMP for EU Approval to Treat Patients with Severe Aplastic Anemia, a Serious Blood Disorder
Cantor Boosts Ligand Pharma Target To $93
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog (Zacks)
Related GSK
Benzinga's Volume Movers
5 NYSE Healthcare Stocks With The Highest ROE
Will Headwinds Weigh on Glaxo's (GSK) Earnings in Q2? - Analyst Blog (Zacks)

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. PROMACTA is the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based therapy due to their low blood platelet counts. PROMACTA in combination with interferon-based therapy has been shown to improve a patient's chance of achieving a sustained virologic response (SVR) or viral cure.

Posted-In: News FDA

 

Related Articles (LGND + GSK)

Get Benzinga's Newsletters